Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jiling Zhu
Institutions:
Zhejiang Chinese Medical University,
Huzhou Normal University,
Huzhou Central Hospital,
Zhejiang University
Observed institutions:
Zhejiang Chinese Medical University,
First Affiliated Hospital of Wenzhou Medical University,
Huzhou Normal University,
Huzhou Central Hospital,
Zhejiang University
ORCID:
0009-0001-4862-5291
Observed ORCID:
0009-0001-4862-5291
OpenAlex ID:
A5081339549
Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab
2025
·
Hanwen Wu
, Jiling Zhu
, et al.
·
JDDG Journal der Deutschen Dermatologischen Gesellschaft
·
25
Efficacy, Safety, and Early Relapse after Cessation of Upadacitinib versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis®: A Real-World Study in China
2024
·
Jiling Zhu
, Hanwen Wu
, et al.
·
Dermatitis
·
19
Vunakizumab for Treatment of Acrodermatitis Continua of Hallopeau: A Case Report and Literature Review
2025
·
Yi Yao
, Yingming Ma
, et al.
·
Psoriasis Targets and Therapy
·
2
PDF
Exazerbation der atopischen Dermatitis nach Behandlungsabbruch und prädiktive Faktoren für die Exazerbation: JAK1‐Inhibitoren versus Dupilumab
2025
·
Hanwen Wu
, Jiling Zhu
, et al.
·
JDDG Journal der Deutschen Dermatologischen Gesellschaft
PDF
Show more works
View as search
Works count:
4
Citation count:
46
H-index:
2
I10-index:
2
Year
Topic
Type